Investment management company Vulcan Value Partners recently released its fourth-quarter 2022 investor letter. A copy of the same can be downloaded here . The firm has five strategies, and all trailed their benchmark indexes in 2022. In the fourth quarter, the fund’s Large-Cap Composite returned 8.2% net of fees and expenses, the Small Cap Composite returned 11.2% net, Focus Composite returned 7.6% net, the Focus Plus composite returned 7.7%, and All Cap Composite returned 7.2% net. You can check the top 5 holdings of the fund to know its best picks in 2022. Vulcan Value Partners highlighted stocks like Abbott Laboratories (NYSE: ABT ) in the Q4 2022 investor letter. Headquartered in North Chicago, Illinois, Abbott Laboratories (NYSE:ABT) is a healthcare products company. On February 8, 2023, Abbott Laboratories (NYSE:ABT)stock closed at $110.20 per share. One-month return of Abbott Laboratories (NYSE:ABT)was -1.04%, and its shares lost 13.74% of their value over the last 52 weeks. Abbott Laboratories (NYSE:ABT)has a market capitalization of $192.141 billion. Vulcan Value Partners made the following comment about Abbott Laboratories (NYSE:ABT) in its Q4 2022 investor letter: “ Abbott Laboratories (NYSE:ABT) is one of the largest and most diversified health care companies in the world. […]
K&X Design and Investment Technology, LLC
Invest The Invisible Impact
K&X Design and Investment Technology, LLC
Invest The Invisible Impact
